Regenxbio Inc (RGNX)
Pretax margin
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
|---|---|---|---|---|---|---|
| Earnings before tax but after interest (EBT) | US$ in thousands | -263,646 | -280,405 | 141,247 | -106,010 | -97,488 |
| Revenue | US$ in thousands | 85,585 | 89,470 | 446,639 | 291,249 | 59,562 |
| Pretax margin | -308.05% | -313.41% | 31.62% | -36.40% | -163.67% |
December 31, 2023 calculation
Pretax margin = EBT ÷ Revenue
= $-263,646K ÷ $85,585K
= -308.05%
The pretax margin of Regenxbio Inc has experienced significant fluctuations over the past five years. In 2019 and 2020, the company reported negative pretax margins of -276.70% and -68.59%, respectively, indicating that the company's operating expenses and interest payments exceeded its revenues before taxes during those years.
However, in 2021, Regenxbio Inc saw a notable improvement in its pretax margin, reaching a positive 30.03%. This increase suggests that the company was able to generate higher revenues relative to its operating costs and interest expenses, resulting in a profit before taxes.
Unfortunately, this positive trend did not continue in the following years, as the pretax margin deteriorated to -248.75% in 2022 and further declined to -292.15% in 2023. These negative pretax margins indicate that the company's losses before taxes widened compared to its revenues during those periods.
Overall, the analysis of Regenxbio Inc's pretax margin shows a mix of profitability and loss-making years, highlighting the fluctuating financial performance of the company over the past five years.
Peer comparison
Dec 31, 2023